Prostate cancer screening 2010: Updated recommendations from the American Cancer Society

Journal of the National Medical Association

Volumn 102, Issue 5, 2010, Pages 423-429

  Brooks, Durado D ^a   Wolf, Andrew M D ^b   Smith, Robert A ^a   Dash, Chiranjeev ^c   Guessous, Idris ^c,d,e  

^a AMERICAN CANCER SOCIETY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c EMORY UNIVERSITY   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; AGE DISTRIBUTION; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; FOLLOW UP; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NON PROFIT ORGANIZATION; PERFORMANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; UNITED STATES;

EID: 77953150271     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30578-2     Document Type: Review

References (51)

1. American Cancer Society. Cancer Facts & Figures for African Americans 2009-2010. Atlanta, GA: American Cancer Society; 2009.
2. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007;177(2):444-449.
3. Christiane Robbins C, Torres JB, Hooker S, et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res. 2007;17(12):1717-1722.
4. Gaston KE, Desok K, Singh S, Ford OH, Mohler JL.Racial Differences in Androgen Receptor Protein Expression in Men With Clinically Localized Prostate Cancer. J Urol. 2003;170(3):990-993.
5. Jones BA, Liu WL, Araujo AB, et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2825-2834. Epub 2008 Sep 30.
6. Oakley-Girvan I, Kolonel LN, Gallagher RP, Wu AH, Felberg A, Whittemore AS. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer. Am J Public Health. 2003;93(10):1753-1759. (Pubitemid 38477646)
7. Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med. 2003;18(10):845-853.
8. Denberg TD, Kim FJ, Flanigan RC, et al. The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Med Care. 2006;44(12):1137-1141.
9. Wolf AMD, Wender RC, Etzioni RB, et al. American Cancer Society guidelines fa the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98.
10. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for earty lung cancer detection. CA Cancer J Clin. 2001;51:38-75.
11. Prostate-Specific Antigen Best Practice Statement: 2009 Update. American Urological Association. http://www.auanet.org/content/guidelines-and-quality- care/clinical-guidelines/main-reports/psa09.pdf. Accessed March 7, 2009.
12. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2008;149:185-191.
13. http://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp. Accessed February 17, 2010.
14. Eyre SJ, Ankerst DP, Wei JT, et al. Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. J Urol. 2009.
15. Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006;68:1152-1155.
16. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534. (Pubitemid 43898816)
17. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452-1455.
18. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HH, Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol. 2001;165:757-760.
19. Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol 1999;162:741-748.
20. Gulati R, Inoue LYT, Katcher J, Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics. 2010 (in press).
21. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA. 2000;284:1399-1405.
22. Agalliu I, Weiss NS, Lin DW, Stanford JL. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Canc Causes Control. 2007;18:931-937.
23. Bergstralh EJ, Roberts RO, Farmer SA, Slezak JM, Lieber MM, Jacobsen SJ. Population-based case-control study of PSA and DRE screening on prostate cancer mortality. Urology. 2007;70:936-941.
24. Weinmann S, Richert-Boe KE, Van Den Eeden SK, et al. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study. Epidemiology. 2005;16:367-376.
25. Concato J, Wells CK, Horwitz RI, et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med. 2006;166:38-43.
26. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA". Int J Cancer. 2001;92:893-898.
27. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med. 2008;23:1809-1814.
28. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325:740.
29. Shaw PA, Etzioni R, Zeliadt SB, et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004;160:1059-1069.
30. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417-424.
31. Horner M, Ries L, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
32. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer - part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
33. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167-170.
34. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
35. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
36. Pinsky PF, Ford M, Gamito E, Higgins D, et al. Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Med Assoc. 2008;100(3):291-298.
37. Barry MJ. Screening for Prostate Cancer - The Controversy That Refuses to Die. N Engl J Med. 2009;360:1351-1354
38. Bunker CH, Patrick AL, Konety BR, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev. 2002;11:726-729.
39. Giri VN, Beebe-Dimmer J, Buyyounouski M, et al. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol. 2007;178:1920-1924;discussion 1924.
40. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-383.
41. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
42. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302:1557-1564.
43. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124-1129.
44. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008;29:534-539.
45. Sanda MG, Dunn RL, Michalski J, et al. Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors N Engl J Med. 358;12:1250-1261.
46. Taylor KL, Davis III JL, Turner RO, et al. Educating African American men about the prostate cancer screening dilemma: a randomized intervention. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2179-2188.
47. Weinrich SP, Boyd MD, Weinrich M, et al. Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. J Cancer Educ. 1998;13(4):213-219. (Pubitemid 29024726)
48. Myers RE, Daskalakis C, Cocroft J, et al. Preparing African-American men in community primary care practices to decide whether or not to have prostate cancer screening. J Natl Med Assoc. 2005;97(8):1143-1154 (Pubitemid 41098542)
49. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
50. Eyre SJ, Ankerst DP, Wei JT, et al. Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. J Urol. 2009.
51. Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006;68:1152-1155.